Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Tadashi Shimada"'
Autor:
Silvia Sayuri Shimada, Camargo da Silva, Livia Graziele Rodrigues, Rhonan Ferreira Silva, Miranda de Torres, Ricardo Tadashi Shimada
Publikováno v:
Bioscience Journal, Vol 32, Iss 5 (2016)
Objective: The present study aimed to investigate the potential of permanent canines for sexual dimorphism in a Brazilian population. Methods: The sample consisted of 172 dental casts from females (n=102) and males (n=70) aged between 13 and 49 years
Externí odkaz:
https://doaj.org/article/522312d3c5874b72ad1c383dc89e76eb
Autor:
Tomohide Tamura, Naoyuki Nogami, Masao Harada, Haruyasu Murakami, Hiroshige Yoshioka, Yuichiro Ohe, Akira Inoue, Makoto Nishio, Kengo Takeuchi, Takashi Seto, Hiroshi Kuriki, Katsuyuki Kiura, Makoto Maemondo, Tadashi Shimada, Kazuhiko Nakagawa, Toyoaki Hida, Tomohiro Tanaka
Publikováno v:
Journal of Clinical Oncology
Purpose Alectinib is an anaplastic lymphoma kinase (ALK) –specific kinase inhibitor that seems to be effective against non–small-cell lung cancer (NSCLC) with a variety of ALK mutations. The primary analysis of AF-001JP reported a promising overa
Autor:
Takeshi Hara, Tadashi Shimada, Akiko Sawada, Maki Sawada, Mayumi Shimizu, Kasumi Maeda, Ayumi Kyuka
Publikováno v:
Journal of Society of Cosmetic Chemists of Japan. 51:147-152
Publikováno v:
Journal of Society of Cosmetic Chemists of Japan. 51:33-40
Autor:
Miyako Satouchi, Kazuhiko Nakagawa, Toyoaki Hida, Takashi Seto, Yuichiro Ohe, Katsuyuki Hotta, Makoto Nishio, Masahiro Tatsuno, Takashi Asakawa, Tadashi Shimada, Tomohiro Tanaka, Toshiaki Takahashi, Tomohide Tamura, Koji Takeda
Publikováno v:
Cancer Science
Summary We report pharmacokinetics, efficacy, and safety data for a new 150 mg alectinib capsule in ALK+ non-small-cell lung cancer in a multicenter, open-label pharmacologic study (JP28927). Eligible patients (≥20 years, locally advanced/metastati
Publikováno v:
Folia Pharmacologica Japonica. 148:197-204
Publikováno v:
Oleoscience. 15:415-421
Autor:
Mayumi Shimizu, Masayuki Takaishi, Kaori Saito, Fumitaka Fujita, Ayumi Yamaguchi, Jun Usukura, Tadashi Shimada
Publikováno v:
Journal of Society of Cosmetic Chemists of Japan. 48:306-311
Autor:
Tomohiro Tanaka, Akira Inoue, Kengo Takeuchi, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Katsuyuki Kiura, Yuichiro Ohe, Tadashi Shimada, Makoto Nishio, Toyoaki Hida, Hiroshige Yoshioka, Tomohide Tamura, Naoyuki Nogami, Masao Harada, Makoto Maemondo, Takashi Seto
Publikováno v:
The Lancet Oncology. 14:590-598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed to study the activity and safety of CH5424802, a potent, selective, and orally available AL
Publikováno v:
Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 148(4)